# Revolution Medicines' Pancreatic Cancer Drug Shows Breakthrough Results

> Revolution Medicines' new pancreatic cancer drug shows strong clinical results, signaling potential shift in cancer treatment approaches
- Title: Revolution Medicines' Pancreatic Cancer Drug Shows…
- Summary: Revolution Medicines' new pancreatic cancer drug shows strong clinical results, signaling potential shift in cancer treatment approaches Revolution…
- Keywords: revolution medicines, daraxonrasib, pancreatic cancer, nasdaq, rvmd, pancreatic cancer treatment, clinical trial, rasonque, fda approval, ai stocks, hedge funds, nasdaq rvmd
- Source: Yahoo Finance — https://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-promising-clinical-143313578.html
- Published: 2026-09-16T14:33:13+00:00
- Read time: 1 min
- Topics: revolution medicines, daraxonrasib, pancreatic cancer, nasdaq, rvmd, pancreatic cancer treatment, clinical trial, rasonque, fda approval, ai stocks, hedge funds, nasdaq rvmd
## New Drug Candidate Results
Revolution Medicines' daraxonrasib drug candidate shows strong late-stage clinical results for pancreatic cancer

> In the Health Care sector, we see compelling long-term idiosyncratic growth opportunities in drug discovery, diagnostics and medical innovation
## Investor Letter Highlight
Parnassus Growth Equity Fund added Revolution Medicines to its Q2 2026 portfolio with strong growth potential

> During the quarter, we added Revolution Medicines, Inc. developer of a promising new drug for pancreatic cancer
## Market Performance
Revolution Medicines shares rose 358% over 52 weeks with $43.91 billion market cap
## FDA Approval
FDA approved Revolution Medicines' Rasonque for metastatic pancreatic cancer treatment
## Investor Outlook
Parnassus Growth Equity Fund sees strong long-term potential in Revolution Medicines' drug development

> Revolution Medicines' lead drug candidate, daraxonrasib, has delivered strong late-stage clinical results in pancreatic cancer
## Key takeaway

Revolution Medicines' daraxonrasib drug candidate shows promise for pancreatic cancer treatment with potential to become new standard of care